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 Abstract 
Diabetic ketoacidosis (DKA) is a state of severe insulin deficiency resulting in 
hyperglycemia, ketoacidosis, and inflammation. Children with DKA have an increased risk 
of microvascular complications (e.g. stroke). The glycocalyx maintains the anti-thrombotic 
properties of endothelial cells (ECs), however the glycocalyx status is unknown in DKA. 
We quantified major glycocalyx components: hyaluronic acid (HA), heparan sulfate (HS), 
chondroitin sulfate (CS), and syndecan-1 in DKA plasma and correlated them with DKA 
severity. HA/HS were significantly increased in the plasma of DKA patients in comparison 
to insulin-controlled type-1 diabetics, but only HA correlated to DKA severity. Exogenous 
addition or removal of HA increased reactive oxygen species generation, while only the 
latter suppressed basal nitric oxide production in cerebral ECs, implicating a prothrombotic 
endothelial response to HA shedding. Exogenous supplementation of HA/HS/CS reduced 
platelet adhesion, suggesting shedding of HA/HS to be a contributor to the prothrombotic 
state of DKA. 
 
 
Keywords 
Diabetic ketoacidosis, glycocalyx, endothelial dysfunction, platelet adhesion, hyaluronic 
acid, heparan sulfate, plasma, nitric oxide, cerebral microvasculature, ROS production, 
ERK2 signaling 
  
  
ii 
 
Co-Authorship Statement  
Dr. Fraser and Dr. Cepinskas have both provided their clinical and scientific expertise to 
build the foundation to this experimental question. Their guidance and advice were used to 
approach experimental questions and interpret result data. Dr. Patterson was also consulted 
on experimental design and data collection. Dr. Stanimorovic (NRC, University of Ottawa) 
provided the primary cerebral microvascular endothelial cells for the in vitro model.  
All texts and figures were generated by student, and then reviewed by Dr. Fraser and Dr. 
Cepinskas. Figure 9 was adapted from M Woo (2015) and new conclusions were added in. 
 
 
  
  
iii 
 
Table of Contents 
 
Abstract ................................................................................................................................. i 
Co-Authorship Statement ................................................................................................... ii 
Table of Contents .............................................................................................................. iii 
Acknowledgments .............................................................................................................. vi 
List of Tables .................................................................................................................... vii 
List of Figures .................................................................................................................. viii 
List of Abbreviations ........................................................................................................... x 
1 « Introduction » ............................................................................................................... 1 
1.1 « Type 1 Diabetes Mellitus » ................................................................................... 1 
1.2 « Diabetic Ketoacidosis » ........................................................................................ 4 
1.3 « Microvascular Dysfunction » ............................................................................... 5 
1.3.1 « Cerebral Edema » .......................................................................................... 5 
1.3.2 « Thrombotic Events (e.g. Stroke) »................................................................. 6 
1.4 « Glycocalyx » ......................................................................................................... 8 
1.5 « Rationale » .......................................................................................................... 12 
1.6 « Hypothesis » ....................................................................................................... 13 
1.7 « Objectives » ........................................................................................................ 13 
2 « Methods » .................................................................................................................. 14 
2.1 « Human Subjects » ............................................................................................... 14 
2.2 « Blood Collection and Processing » ..................................................................... 14 
2.3 « Glycocalyx Enzyme Linked Immunoassay » ..................................................... 15 
  
iv 
 
2.4 « Human Cerebral Microvascular Endothelial Cells » .......................................... 15 
2.5 « Reactive Oxygen Species and Nitric Oxide Measurement » .............................. 16 
2.6 « Western Blotting of Extracellular Regulated Kinases (ERK) » ......................... 17 
2.7 « Platelet Adhesion Assay » .................................................................................. 18 
2.8 « Statistical Analysis » .......................................................................................... 19 
3 « Results » ..................................................................................................................... 20 
3.1 « Study Patients » .................................................................................................. 20 
3.2 « ELISA measurements of plasma glycocalyx constituents » ............................... 21 
3.3 « Plasma glycocalyx correlations with DKA severity » ........................................ 23 
3.4 « Endothelial Reactive Oxygen Species (ROS) Assay » ....................................... 25 
3.5 « Endothelial Nitric Oxide Production Assay » .................................................... 27 
3.6 « Western Blotting of Phospho-ERK1/2 and Total ERK1/2 » .............................. 28 
3.7 « Platelet Adhesion Assay » .................................................................................. 31 
3.8 « Negative Experimental Data » ............................................................................ 32 
4 « Discussion » ............................................................................................................... 33 
4.1 « Glycocalyx Status in DKA » .............................................................................. 33 
4.1.1 « Increased HA in DKA Plasma ..................................................................... 34 
4.1.2 « Increased HS in DKA Plasma ..................................................................... 36 
4.1.3 « Source of Glycocalyx Shedding » ............................................................... 36 
4.1.4 « Consequences of Glycocalyx Shedding » ................................................... 38 
4.2 « Microvasculature Dysfunction » ........................................................................ 39 
4.2.1 « Increased ROS after HA Cleavage » ........................................................... 39 
  
v 
 
4.2.2 « Decreased NO after HA Cleavage » ............................................................ 39 
4.2.3 « Increased ERK2 phosphorylation under HYALase-treated HBMEC » ...... 41 
4.3 « Inhibition of Platelet Adhesion via Enhanced Glycocalyx » .............................. 42 
4.4 « Clinical Significance and Limitations » ............................................................. 44 
4.4.1 « Clinical Significance »................................................................................. 44 
4.4.2 « Limitations » ................................................................................................ 44 
4.4.3 « Future Directions » ...................................................................................... 45 
4.5 « In Conclusion » ................................................................................................... 46 
References ......................................................................................................................... 49 
Appendices ........................................................................................................................ 61 
Curriculum Vitae ............................................................................................................... 71 
 
  
  
vi 
 
Acknowledgments 
I would like to thank my supervisors, Dr. Fraser and Dr. Cepinskas, for their 
guidance, scientific expertise, and patience they have given me during these two years; I 
could not have learned more from this wonderful pair. My gratitude also goes out to my lab 
colleagues: Dr. Patterson, Inga Cepinskas, and Dr. Iida for their time, advice, and scientific 
knowledge in helping me with experimental troubleshooting. I would also like to thank Dr. 
Carolina Gillio-Meina for collecting and handling of the plasma samples from The 
Translational Research Centre (London, ON). Thank you to my advisory committee, Dr. 
Gill and Dr. Regnault for their advice and guidance as well.  
 
  
vii 
 
List of Tables 
Table 1. Patient Clinical Data of Insulin-controlled Type-1 Diabetes Mellitus Patients 
(CON) or with Acute Diabetic Ketoacidosis (DKA)............................................................ 20 
 
  
  
viii 
 
List of Figures 
Figure 1. Schematic representation of the glycocalyx at the brain cerebral microvasculature.
 .............................................................................................................................................. 11 
Figure 2. Schematic flowchart of hypothesis, objectives, and clinical relevance to DKA. . 13 
Figure 3. Plasma Glycocalyx Constituents in Patients with Insulin-controlled Type-1 
Diabetes Mellitus (CON) or Acute Diabetic Ketoacidosis (DKA). ..................................... 22 
Figure 4. Correlations between plasma glycocalyx constituents and DKA parameters in 
DKA patients. ....................................................................................................................... 25 
Figure 5. Effect of exogenous LMW HA and HYALase on ROS production in naïve 
(unstimulated) HBMEC. ....................................................................................................... 26 
Figure 6. Effect of exogenous LMW HA and HYALase on NO production in naive 
(unstimulated) HBMEC. ....................................................................................................... 28 
Figure 7. ERK1/2 phosphorylation in HBMEC stimulated with HYALase. ....................... 30 
Figure 8. Platelet adhesion on HBMEC monolayers grown in normal EBM-2+ (CON) or 
EBM-2+ with GAGs supplementation (+HA/HS/CS). ........................................................ 32 
Figure 9. Proposed mechanism of microvascular dysfunction leading to CE and thrombosis 
in DKA patients as adapted from Woo (2015)204. ................................................................. 47 
 
 
 
  
  
ix 
 
Supplementary Figure 1. Plasma HYALase activity in insulin-controlled T1DM (CON) and 
DKA patients. ....................................................................................................................... 61 
Supplementary Figure 2. HA detected by ELISA in Supernatents of HBMEC monolayers 
with or without HYALase treatment. ................................................................................... 62 
Supplementary Figure 3. Densitometric quantification of ERK1 phosphorylation in 
HBMEC stimulated with HYALase ..................................................................................... 63 
Supplementary Figure 4. Resistance Measurements of LMW HA or HYALase on naïve 
HBMEC cells via Electric Cell-substrate Impedance Sensing (ECIS) ................................ 64 
Supplementary Figure 5. HBMEC Permeability after Heparinase and/or HYALase 
treatment determined via Fluorescein isothiocyanate-Dextran ............................................ 65 
Supplementary Figure 6. PMN adhesion and rolling after treatment of HYALase and/or 
Heparinase on naïve HBMEC monolayers. .......................................................................... 67 
Supplementary Figure 7. PMN adhesion and rolling after treatment of HYALase on naïve 
HBMEC monolayers and PMNs. ......................................................................................... 68 
Supplementary Attachment 1: Ethics approval .................................................................... 70 
 
  
  
x 
 
List of Abbreviations 
BBB  Blood-Brain Barrier 
BCA  Bicinchoninic acid 
BSA  Bovine serum albumin 
CAV-1 Caveolin-1 
CE  Cerebral edema 
CED  Cerebral endothelial dysfunction 
CMFDA 5-chloromethylfluorescein diacetate 
CON  Control 
CRP  C-reactive protein 
CS  Chondroitin Sulfate 
CXCL  C-X-C- chemokine ligand 
DAF-FM 4-Amino-5-methylamino-2',7'-difluorofluorescein diacetate 
DAMP  Danger-associated molecular pattern 
DETA  Diethylenetriamine 
DHR  Dihydrorhodamine-123 
DKA  Diabetic ketoacidosis 
EC  Endothelial cell 
ECIS  Electric cell-substrate impedance sensing 
  
xi 
 
ELISA  Enzyme-linked immunosorbent assay 
eNOS  Endothelial nitric oxide synthase 
GAG  Glycosaminoglycan 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
HA  Hyaluronic acid 
HARE  Hyaluronic acid receptor for endocytosis 
HAS  Hyaluronic synthase 
HbA1c  Hemoglobin A1C 
HBMEC Human brain microvascular endothelial cells 
HBSS  Hank’s balanced salt solution 
HCO3  Bicarbonate 
HLA  Human leukocyte antigen 
HMW  High molecular weight 
HS  Heparan sulfate 
IFN  Interferon  
IL  Interleukin 
IαI   Inter-alpha-trypsin Inhibitor 
LMW  Low molecular weight 
MAPK  Mitogen-activated protein kinase 
  
xii 
 
MMP  Matrix metalloproteinase  
MMW  Medium molecular weight 
NHE  Sodium-hydrogen exchanger 
OD  Optical density 
PAF  Platelet activating factor 
PBS  Phosphate buffered saline 
PMN  Polymorphonuclear neutrophils 
RHAMM Receptor for hyaluronan mediated motility 
RT  Room temperature 
SDC-1  Syndecan-1 
SDS  Sodium dodecyl sulfate 
SEM  Standard error of the mean 
T1BDM Type-1B Diabetes mellitus 
T1DM  Type-1 Diabetes mellitus 
T2DM  Type-2 Diabetes mellitus 
TBS  Tris-buffered saline 
TBS-T  Tris-buffered saline with Tween-20 
TLR  Toll-like receptor 
TNF  Tumor necrosis factor 
  
xiii 
 
vWF  von Willebrand factor 
 
 
 
1 
 
 
 
1 « Introduction » 
1.1 « Type 1 Diabetes Mellitus » 
Type 1 Diabetes Mellitus (T1DM) is a chronic condition that is usually diagnosed in 
children, but can go asymptomatic until adolescence or early adult years87. T1DM is 
normally characterized by the presence of autoantibodies targeting the production or the 
release of insulin from ß-islet cells of the pancreas. In order to maintain their glucose levels 
within a normal range (4-10 mmol/L in children, dependent on age), life-long usage of 
exogenous insulin is required9. This differs from the more commonly diagnosed Type 2 
Diabetes Mellitus (T2DM), where exogenous insulin cannot regulate their blood glucose 
levels due to cells being insulin-resistant, rather than degeneration of the ß-islets87. Insulin 
is a short peptide hormone that regulates the uptake of glucose into cells and is a key 
maintainer of glucose homeostasis within the body87. There is also an idiopathic subset of 
T1DM called Type 1B Diabetes Mellitus (T1BDM) where no circulating autoantibodies 
can be found but the clinical symptoms of T1DM are seen7. Both T1BDM and T2DM tend 
to affect older patients (> 20-30 years old), however T2DM incidence have recently seen an 
increase in the younger population9. Onset of T1DM occurs most frequently during puberty 
(10-14 years old), with more females being earlier diagnosed than males due to females 
naturally maturing faster87. This disproportion balances out when looking at the adult 
population of T1DM. All three types of DM commonly suffer from the lack of insulin 
regulation causing endocrine and metabolic dysregulation between the fed and the fasted 
state87.  
The cohort of T1DM patients are affected by both genetic and environmental 
influences on the risk of disease onset211,212. Researchers compared the haplotypes of 
T1DM antigen presenting molecules, which is encoded on the human leukocyte antigen 
(HLA) region on chromosome 6, to determine the genetic influence of T1DM. Two 
haplotypes have been implicated as a major risk factor for T1DM and the development of 
ß-cell autoantibodies, HLA-DR4-DQ8 and HLA-DR3-DQ2.  HLA-DR4-DQ8 is associated 
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with the development of autoantibodies targeted to the insulin pathway first, while HLA-
DR3-DQ2 is associated with the development of glutamate decarboxylase 2 (GAD65, a 
protein on insulin secretory vesicles) autoantibodies first16. The risk of T1DM within five 
years of the first detected autoantibody related to insulin increases dramatically as more 
unique autoantibodies targeting insulin production and secretion are found212. In 
monozygous twin studies, it has been shown that having the haplotype only provided a 
concordance of 30%, leading researchers to look at both the geographic and gestational 
environment153. One of the most common countries with T1DM haplotypes is Sweden and 
a study has shown that HLA-DR-DQ haplotypes who immigrated to Sweden had a higher 
risk of disease onset, implicating environmental factors47. The amount of infections could 
also determine disease onset as a study done in Russia showed that in similar risk-
haplotype groups, children who had more infections over their lifetime had a lower risk of 
developing autoantibodies towards insulin production and secretion93. Gestational events, 
such as decreased choline-containing phospholipids in cord blood can also be a predictor of 
T1DM development100.  
The progression through T1DM can be separated into three stages. Stage 1 consists 
of finding autoantibodies targeted to insulin or to any tyrosine phosphatase-like molecules 
(e.g. GAD65, IA-2, or ZNT8) that are involved in secretion of vesicles from the ß-cells of 
the pancreas87. Stage 2 occurs when blood glucose is elevated causing hyperglycemia, as 
cells are not uptaking glucose from the blood due to the lack of circulating insulin. Stage 3 
is when clinical onset of T1DM occurs with physical symptoms appearing such as 
dehydration, polyuria, hyperglycemia, lack of insulin, and around 70-90% ß-cell loss due to 
inflammatory responses from dendritic cells, T-cells, B-cells, and macrophages87,96. The 
initial triggering event to activate autoantigens of the ß-cells is unknown but has been 
suggested that onset can be triggered by viral and environmental events213. Both 
autoantigen-specific CD4+ and CD8+ T-cells can be found within circulation and provoke 
the response of further release and distribution of autoantibodies targeted to the ß-cells38. 
Loss of heparan sulfate (HS), a component of the glycocalyx, in the basement membrane of 
islets also correlated with ß-cell death in diabetic mice models, implicating a pathology of 
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more than just auto-inflammation164. However, it is elusive as to whether chronic 
inflammation or an episode of rapid ß-cell mass loss due to infiltrating inflammatory cells 
are responsible for activating the clinical onset symptoms of T1DM87.  
The development of insulin-based therapy vastly reduced mortality69 and healthcare 
costs169 of T1DM as patients were able to manage their glucose levels and reduce metabolic 
dysfunction episodes48.  Consistent monitoring of glucose levels have developed insulin 
pumps where insulin is automatically injected when needed, leading to improved glycemic 
control and fewer hypoglycemic episodes11.  Insulin treatment is also speculated to reduce 
the immune response towards ß-cells post-treatment due to reduced production of insulin. 
Unfortunately, T1DM patients are still at a 2-4 fold higher risk of death, mainly attributed 
to increased risk of cardiovascular disease87. Consistently elevated glucose levels have been 
associated with both chronic macrovascular and microvascular disease progression. The 
macrovascular complications include increased risks of coronary heart disease, stroke, 
cerebrovascular disease and peripheral artery disease180. Frequent hyperglycemia episodes 
also partially contribute to the macrovascular complications by creating aversive osmotic 
fluid loads on both the renal and heart systems over time. During hyperglycemia, an 
overproduction of reactive oxygen species (ROS) also occurs due to a compensation 
mechanism of the mitochondrial electron transport chain from hypoglycemic cells144. 
Excessive ROS plays a deleterious role by reducing the responsiveness of the 
microvasculature89, putting DM patients at higher risk for the development of nephropathy, 
neuropathy and retinopathy87. Diabetic nephropathy occurs in 40% of T1DM, which is 
initially indicated by microalbuminuria, an increase in albumin secretion152. 
Microalbuminuria can proceed into macroalbuminuria, and then lead to chronic kidney 
disease, or it can also regress to normoalbuminuria. 
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1.2 « Diabetic Ketoacidosis » 
One of the highest risks of mortality can occur at the onset of T1DM, when the 
patient is unaware they are no longer producing sufficient insulin, resulting in a metabolic 
dysregulation and a lack of uptake of glucose within cells87. Diabetic ketoacidosis (DKA) is 
a life-threatening condition that occurs when metabolic acidosis, hyperglycemia, and 
ketonemia are simultaneously present in the patient. As glucose cannot be used as the 
primary fuel, fats (e.g. lipids) are broken down to acetoacetic and ß-hydroxylbutyric acids 
(ketones), which are naturally acidic, via lipolysis171. Excessive production of ketones 
(ketonemia) also acidifies the blood and overloads the bicarbonate buffering capacity 
causing ketoacidosis200. The lack of glucose uptake also switches muscles to anaerobic 
metabolism leading to the production of acidic lactate, further disrupting the acid-base 
homeostasis within the blood leading to metabolic acidosis35. The severity of the DKA 
episode is determined by the level of acidity in the blood, with mild DKA having a venous 
pH of 7.2-7.3, while moderate DKA has a pH of 7.1-7.2, and severe DKA has a pH of < 
7.1200.  
The body attempts to compensate for the lack of glucose within cells via 
gluconeogenesis and glyconeolysis; both processes that exacerbate hyperglycemia as cells 
are unable to uptake the glucose molecules from the blood without insulin171. The lack of 
feedback from insulin to inhibit stress hormones such as glucagon, epinephrine, growth 
hormone, and cortisol only further releases more glucose into the blood stream200. For 
example, glucagon’s main function is to stimulate the production of ketone bodies in the 
liver and increase hepatic glucose production to be secreted into the blood stream171. 
Hyperglycemia also induces osmotic diuresis in the renal system. As more glucose is 
secreted into the urinary system for excretion, not only is water osmotically drawn with 
glucose; potassium, sodium, calcium, magnesium, chloride, and phosphate are also 
excreted resulting in a net loss200. Along with the loss of previously mentioned ions, the 
ketoanion excretion of excessive ketones require simultaneous cation excretion.  As water 
is lost, progressive volume depletion leads to decreased glomerular filtration, reduced 
5 
 
 
 
glucose and ketone excretion, and exacerbation of the plasma tonicity imbalance171. 
Presenting clinical symptoms would be dehydration, polyuria, vomiting, weakness, 
abdominal pain, tachycardia, and Kussmaul breathing (deep respirations to eliminate blood 
CO2)
200. Eventually, the patient suffers reduced consciousness and enter a comatose state if 
left untreated. Primary treatment goals are to restore circulatory fluid balance and infuse 
insulin and electrolytes to treat hyperglycemia, hyperosmolality, and ionic imbalances171. 
 
1.3 « Microvascular Dysfunction » 
DKA patients account for over 1 billion in healthcare costs in the United States and 
about 30% of newly diagnosed T1DM will experience a DKA episode145. DKA can be fatal 
if treated late or due to secondary complications, including sepsis, pneumonia, acute 
respiratory distress syndrome, cardiac arrhythmias, or rhabdomyolysis, which all contribute 
to the mortality risk of DKA200. However, two of the major contributors to secondary 
complications, cerebral edema (inflammatory response) and stroke (prothrombotic 
response), involve microvascular dysfunction and are discussed below.  
 
1.3.1 « Cerebral Edema » 
 Cerebral edema (CE) is one of the major microvascular dysfunctions in DKA 
where the blood-brain barrier (BBB) permeability increases leading to fluid influx into the 
extracellular space of the brain1,55,186. The incidence of CE occurs in 0.5-1% of DKA 
episodes, but the mortality rate can climb to 24% in CE and even those who survive suffer 
permanent neurological injury in 26% of the cases145,155. Initial CE seen in DKA patients 
are considered vasogenic, where the loss of BBB integrity is facilitated by the DKA-
specific inflammatory profile187,200. Increased glucose5, C-reactive protein53,98, and 
ketone136 levels in the blood can create a proinflammatory cascade on endothelial cells 
(ECs) to increase the permeability of the BBB over several months of hyperglycemia. DKA 
6 
 
 
 
patients have a specific upregulation of cytokines (chemokine C-X-C motif ligand (CXCL)-
1, interleukin (IL)-8, IL-6, interferon (IFN) α-2)129, matrix metalloproteinases (MMP) 
8/9202, and increased activation of polymorphonuclear neutrophils (PMNs)203, all capable of 
causing cerebral endothelial dysfunction (CED) and endothelial injury contributing to the 
vasogenic CE. These cytokines/MMPs can further elicit intracellular signaling, involving 
multiple protein kinases208 (e.g. mitogen-activated protein kinases, MAPK) to facilitate 
increases in paracellular permeability and/or degradation of junctional proteins4.  
Many DKA cases will present subclinical CE upon admission that may be 
exacerbated or resolve during treatment112. The risk of CE has been found to be related to 
the severity of the acidosis, metabolic derangement, and usage of bicarbonate as a 
treatment108. While insulin administration rates have shown a mild individual correlation to 
the risk of CE188, insulin has also been known to upregulate the sodium-hydrogen 
exchanger (NHE) activity, allowing water to flow with sodium into cells during DKA 
therapy186. In fact, using a NHE inhibitor reduced the cellular swelling during treatment of 
insulin and/or alkalization (bicarbonate therapy) in a DKA model158, displaying how during 
DKA treatment, the vasogenic CE can become cytotoxic edema. Cerebral autoregulation of 
blood flow is also impaired at DKA onset, where metabolic abnormalities such as increased 
lactic acid in the brain leads to cerebral vasomotor paralysis156. During correctional fluid 
treatment, vasoconstriction caused by hypocapnia66 can be reversed. However, without 
cerebral autoregulation, the vessels may vasodilate too far during treatment and increase 
cerebral blood flow to facilitate CE, as DKA patients have normal to increased cerebral 
blood perfusion rates156. Cerebral autoregulation can then play a role in contributing to the 
development of cerebral edema seen in DKA.  
 
1.3.2 « Thrombotic Events (e.g. Stroke) » 
Pediatric DKA patients are also at an increased risk for ischemic or hemorrhagic 
stroke due to a predisposed prothrombotic state, accounting for 10% of the intracerebral 
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complications in DKA58. For example, deep vein thrombosis due to catheter insertion in 
pediatric DKA patients are at a 50% increased rate compared to non-diabetic controls70. 
Thrombosis occurs when prothrombotic factors overwhelm the antithrombotic properties 
(usually found from the vessel wall) and blood begins to stasis due to hypoperfusion. 
Prothrombotic factors such as von Willebrand factor (vWF) stored in ECs, megakaryocytes, 
and platelets can be released under high shear stress, damage to vessel walls68, or hypoxia 
episodes53. While antithrombotic properties of ECs include the tonic production of nitric 
oxide (NO) to prevent the release of vWF68, storage of coagulation factors on the 
glycocalyx136, and inhibitory regulation of P-selectin needed for platelet adhesion53.  
Several systemic inflammatory factors, such as increased PMN degranulation in 
DKA can contribute to the prothrombotic state. Increased degranulation of PMNs can be 
correlated to coronary thrombotic events19 and leukocytes themselves can release platelet-
activating factor (PAF) to facilitate platelet aggregation25. IL-8, a cytokine found to be 
increased in DKA138, is also a potent stimulator of PAF on PMNs23. Acute hyperglycemia 
has also been correlated to increased platelet aggregation159 while chronic hyperglycemia is 
correlated to impaired fibrinolysis (removal of clot)82,105. 
Clinically, DKA patients present a perturbed endothelium157 with elevated levels of 
vWF, prothrombin fragments, and decreased protein C activity27, which are all factors that 
contribute to the prothrombotic state. Even after the DKA episode, T1DM patients continue 
to have a prothrombotic state through increased vWF, prothrombin fragments58, 
hypercoagulability15, and a sustained increase risk in venous thromboembolism compared 
to healthy controls148. Vasoconstriction caused by hypocapnia66, along with dehydration 
and increased blood viscosity due to acidemia all contribute to hypercoagulability58. 
Consequently, hypercoagulability leads to an increased risk of ischemic brain infarctions 
originating from either a stroke, hypoxia, or CE pathogenesis14. The microvasculature is 
especially susceptible to disseminated intravascular coagulation where small vessels are 
blocked by thrombi, leading to a lack of clotting factors and excessive bleeding in 
hemorrhagic conversions from stroke or hypoxia49.  
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1.4 « Glycocalyx » 
 One of the major antithrombotic properties of ECs is the glycocalyx, a mediator in 
NO production and release of anti-coagulation factors. All cells possess a glycocalyx, and 
the endothelial glycocalyx is known to extend 400-500 nm above the cell surface154. The 
glycocalyx is a layer on the surface of cells composed of glycosaminoglycogans (GAGs) 
bound to proteoglycans embedded within the cell membrane (Figure 2). These GAGs serve 
to regulate vascular homeostasis through mediating signal transductions117. The three most 
common GAGs found within the glycocalyx are heparan sulfate (HS), chondroitin sulfate 
(CS), and hyaluronic acid (HA)154. HS and CS are both negatively charged sugar moieties 
that are bound to various proteoglycans such as syndecans, glypicans, and perlecans154. The 
last commonly found GAG, HA, differs from the smaller two GAGS and is a large 
hydrophilic sugar polymer (> 1000 kDa) that is capable of self-assembly or binding onto 
several hyaladherins such as CD44, receptor for HA mediated motility (RHAMM/CD168), 
HA receptor for endocytosis (HARE), and tumor necrosis factor (TNF)-stimulated gene 
6154.  
The glycocalyx acts as a physical barrier to any molecules larger than 70 kDa, 
including cells (e.g. red blood cells). As a result, the endothelial glycocalyx reduces the 
effective diameter of the capillary, which contributes to the high resistance found in the 
microvasculature154. The GAGs in the glycocalyx also contribute to the anticoagulation 
cascade, ROS scavenging, as targets of signal transduction into the cell, as modulators of 
the inflammatory response, and the lubrication and cushioning of the joints52. The 
glycocalyx is capable of detecting changes in the local environment and adapting, such as 
increasing GAG production under high shear stresses or shedding of GAGs within minutes 
of TNF-α stimulation12. As an inflammatory mediator, the length of the glycocalyx 
normally obscures the binding of platelets and leukocytes through hiding the ligands 
(L/P/E-selectins) for adhesion117. Not only are the ligands covered, but the glycocalyx 
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constituents act as a steric barrier preventing platelets and leukocytes from adhering45,154. 
Therefore, under inflammatory stimulation the glycocalyx is often shed to reveal the 
receptors and allow the inflammatory response to proceed60. Studies have shown that under 
many inflammatory conditions such as stimulation of TNF-α135, hyperglycemia133, 
endotoxemia127, increased oxidized low-density lipoprotein12, and ischemia-reperfusion 
injury31 can reduce the thickness of the glycocalyx, implicating the glycocalyx as a 
functional step in responding to an inflammatory response from ECs64.  
Heparan sulfate chains are mostly made up of disaccharides of a hexuronic acid and 
D-glucosamine, with variations of sulfate groups and epimerization of D-glucosamine165. 
Heparan sulfate makes up about 50-90% of the chains found in the glycocalyx and its major 
role is to detect flow-induced shear responses, modulate the NO response, activation of 
coagulation inhibition factors (e.g. antithrombin), and inhibition of cytokines such as 
interferon-gamma (IFN-y)154. The ability to detect shear stress and respond to increased 
blood flow is facilitated by the glycocalyx. Specifically, it has been found that HS chains 
are required to produce the elongated morphological response to shear stress and activate 
shear-induced nitric oxide production under flow conditions118. Loss of HS also results in 
impaired phosphorylation of endothelial NO implicating a role of the glycocalyx in proper 
nitric oxide regulation57. The role of HS when shed also shows a damage-associated 
molecule pattern (DAMP), which includes activation of leukocytes and inflammatory 
pathways145.  
Chondroitin sulfate chains are composed from repeating disaccharides of D-
glucuronic acid and N-acetylgalactosamine194. They can be found in a 1:4 ratio to HS but 
are known to be abundantly expressed in the central nervous system52. Removal of CS can 
increase axonal growth within areas of glial scars by stimulating neurite outgrowth99,52. 
Syndecans (SDC-1), are plasma-membrane embedded proteoglycans that attaches both HS 
and CS chains and expresses a tightly regulated expression pattern that varies depending on 
the chemokine stimulation75. The physical interaction between HS, CS, and SDC-1 can 
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therefore lead to connected downstream responses if the shedding of the glycocalyx 
targeted the core proteins of HS and CS.  
Hyaluronic acid makes up about 40% of the glycocalyx and plays a role in detecting 
shear forces, cell motility, and activating proinflammatory or anti-angiogenic pathways63. 
Consisting of repeating disaccharides (D-glucuronic acid and N-acetyl-D-glucosamine), 
HA is hygroscopic due to hydrogen bounds holding onto water and maintaining the 
standalone structure of HA85. The length of HA dictates its main function, with short, low 
molecular weight (LMW) HA (< 250 kDa) inducing a proinflammatory phenotype in ECs, 
while long, high molecular weight (HMW) HA ( > 1000 kDa) promotes an 
immunosuppressive phenotype by inhibiting cell growth and negatively regulating TLR 
signaling21. Short HA can also function as a DAMP and directly upregulate IL-8 and MMP-
2 expression in human endothelial and melanoma cell lines175. HA is also the only part of 
the glycocalyx that does not require binding to a proteoglycan when on the cell surface, but 
it can bind to CD44, a cell-surface glycoprotein, which is usually involved in cell migration 
and wound healing85. Although CD44 is present on platelets and megakaryocytes, allowing 
for adherence onto HA94, CD44-negative platelets have been shown to be prothrombotic in 
a mouse model, possible suggesting a dual role110. Various cell surface receptors, 
glycoproteins, and cell adhesion molecules are covered and overlaid by the glycocalyx, 
protecting ECs from activation of coagulation cascades by platelets and inflammatory 
cascades by leukocytes154. 
Therefore, the constituent changes in GAGs that are associated either with the 
production or release of GAGs from the glycocalyx can serve as a marker of endothelial 
activation and dysfunction91. Relevant to the pathology of T1DM, a recent study has shown 
that the loss of HS at the basement membrane of ß-islets promoted the infiltration of 
leukocytes and correlated with the amount of ß-cell loss in an animal T1DM model87. SDC-
1 levels were also recently found as an independent predictor of mortality among trauma 
patients86. In post-mortem patients of stroke, increased HA deposition in the blood vessels, 
intracellularly, and nuclei were found in the ECs and inflammatory cells from the regions 
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of stroke in the brain2. In endothelial inflammatory diseases such as microalbuminuria, 
there are correlations between the reduced size of the glycocalyx and progression of disease 
on renal ECs132. Within animal sepsis models, prevention of glycocalyx degradation or 
providing GAGs constituents improved the survival of sepsis132. Shedding of the 
glycocalyx has been implicated in the inflammatory process in aneurysmal subarachnoid 
hemorrhage181, atherosclerosis193, T2DM133, cardiac arrest210, trauma36, and chronic kidney 
disease140. It is clear that the glycocalyx is a modulator of the endothelial dysfunction in 
multiple diseases. 
 
Figure 1. Schematic representation of the glycocalyx at the brain cerebral 
microvasculature. 
On the surface of most cells exist a surface layer called the glycocalyx. Major components 
include glycosaminoglycans (GAGS; heparan sulfate (HS), hyaluronic acid (HA), 
chondroitin sulfate (CS)), and proteoglycans (e.g. syndecan-1 (SDC-1))154. Most 
glycoproteins (e.g. CD44, selectins) used in cell-to-cell signaling are covered from the 
bloodstream by the dense GAGs. HS and CS are most commonly found bound to SDC-1 or 
other proteoglycans, while HA can be found aggregating with itself to form a sticky viscous 
layer, or bound to CD44154. The negatively charged GAGs play a role in inflammatory 
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signaling, as they can act as binding sites for chemokines, cytokines, and platelet activating 
factors, while also attenuating access to endothelial cell adhesion molecules117. The 
glycocalyx also serves as a mechanotransducer, affecting nitric oxide production and 
changes in vascular tone154. The structural stability of the glycocalyx is independently 
contributed by each GAG, as removal of one GAG does not affect the structural integrity of 
another GAG. Collectively, the GAGs act as a negative steric barrier to the constituents 
found in the open vasculature209.  
 
1.5 « Rationale » 
The state of the endothelial glycocalyx in DKA patients has yet to be determined 
and how the glycocalyx may contribute to the CED in the context of CE and thrombosis 
has not been eluded. Although there is clinical evidence to suggest that the blood of DKA 
patients are prothrombotic27,116, a recent study using thromboelastography did not find any 
differences in coagulability and instead suggested the injured endothelium as the 
contributor to facilitating the prothrombotic state of DKA183. The glycocalyx covers 
essential ligands (P-selectins) used by both platelets and PMNs to initiate rolling and 
adhesion127,134. The endothelial glycocalyx may then play a role in revealing ligands to 
facilitate PMN activation, leading to the release of cytokines and platelet activation and 
adhesion. Systemic inflammatory models such as hemorrhagic shock76, sepsis170, and 
trauma151 are all in a prothrombotic state26,184 and maintenance of the glycocalyx layer led 
to better outcomes indicating that the glycocalyx may be a therapeutic avenue in preventing 
thrombosis in DKA. Therefore, the breakdown of the glycocalyx at the cerebral 
microvasculature should be investigated to determine if it can facilitate a proinflammatory 
and/or prothrombotic state as seen in DKA (Figure 2). 
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1.6 « Hypothesis » 
I hypothesize that shedding of the glycocalyx from the vascular endothelium would 
be increased in the plasma of DKA patients in comparison to age/sex matched insulin-
controlled T1DM patients. Any elevations of glycocalyx constituents found in the plasma 
of DKA patients will also correlate to DKA severity and removal of the constituent from 
human brain cerebral microvasculature in vitro will also result in a prothrombotic and 
inflammatory profile. 
 
1.7 « Objectives » 
 To examine plasma glycocalyx constituents in pediatric DKA and insulin-controlled 
T1DM patients and to correlate DKA glycocalyx levels with DKA severity  
 To examine exogenous removal and addition of glycocalyx constituents and its 
effect on inflammatory activation on human brain cerebral microvasculature 
endothelial cells (HBMEC)  
 To examine exogenous addition of glycocalyx constituents and its effect on platelet 
adhesion on HBMEC 
 
Figure 2. Schematic flowchart of hypothesis, objectives, and clinical relevance to DKA.  
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2 « Methods » 
This study was approved by the Health Sciences Research Ethics Board at Western 
University. Patient recruitment took place in our regional tertiary care centre at The 
Children's Hospital, London Health Sciences Centre (London, ON, Canada) (Suppl. 
Attachment 1). 
 
2.1 « Human Subjects » 
Consent for research was procured from the legal guardians of all pediatric patients and 
assent was also obtained from T1DM control patients. Pediatric patients considered as 
DKA must meet the following biochemical diagnostic criteria: hyperglycemia >11 mmol/l, 
bicarbonate <15 mmol/l, and ketonuria. A majority of the DKA cases used in this study 
were considered severe (venous pH < 7.1), following these classifications of mild (pH < 
7.3) and moderate (pH < 7.2).  For controls, insulin controlled T1DM with an HbA1C < 
10% and no DKA in the past 3 months were age-sex matched with the study’s DKA 
patients. Insulin-controlled T1DM patient data were obtained on routine check-up, while 
DKA patients were recruited upon admission to the emergency department. As a result, 
certain parameters as seen in Table 1 are missing for CON patients as those parameters are 
not routinely measured during visits.  
 
2.2 « Blood Collection and Processing » 
Blood from T1DM patients was obtained upon hospital presentation and at the time 
of clinically required blood draws. Procedure of collecting and transporting blood has been 
standardized according to Translational Research Centre62 (www.translationalresearch.ca; 
London, ON). Briefly, citrate-containing tubes (Vacutainers®; BD Biosciences, 
Mississauga, ON) were used as an anticoagulant and blood was centrifuged at 1,500 g for 
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15 min at 4°C to separate the plasma component. The upper plasma layer was collected into 
250 μl aliquots and stored at -80°C before thawed on ice for experimental use. Freeze-thaw 
cycles were avoided to prevent any further degradation of glycocalyx components.  
 
2.3 « Glycocalyx Enzyme Linked Immunoassay » 
Plasma concentrations of several major constituents of the glycocalyx were 
measured via enzyme linked immunosorbent assay (ELISA): SDC-1 (1:2 dilution; 
ab46506, Abcam, Cambridge, UK), HS (1:10 dilution; HU8718, Biotang Inc., Lexington, 
MA), CS (1:2 or 1:50 dilution; HU8720, Biotang Inc.), HA (1:8 dilution; DHAYL0, R&D 
Systems, Minneapolis, MN). Plasma samples were assessed in duplicate. Both DKA and 
CON patients’ plasma were used in each assay and dilution factors were adjusted 
accordingly to determine actual plasma concentrations. Media of treatment conditions as 
explained in the nitric oxide and reactive oxygen assay were also assessed for hyaluronic 
acid content in duplicate.  
 
2.4 « Human Cerebral Microvascular Endothelial Cells 
» 
The primary human brain microvascular ECs (HBMEC; AngioProteomie, Boston, 
MA) were used as a model of the brain microvascular endothelium in vitro and as a 
representation of where the two main secondary complications (i.e. CE and stroke) of DKA 
occurs. HBMEC cultures were maintained in Endothelial Growth Basal Medium (EBM-2; 
Clonetics®, Lonza, Basel, Switzerland) supplemented with Clonetics® EGM®-2 MV 
SingleQuots kit (Lonza), 0.1% Gentamycin/Amphotericin (GA-1000; Lonza) on fibronectin 
(1 g/ml in phosphate buffered saline (PBS); Sigma-Aldrich) coated T-75 plates (Sarstedt, 
Nümbrecht, Germany). The cells were kept at 37°C in a humidified atmosphere with 5% 
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CO2 and reseeded when the cell monolayer became 70-80% confluent. HBMEC used in the 
experiments were limited to passages 7-15 to prevent loss of primary characteristics. 
 
2.5 « Reactive Oxygen Species and Nitric Oxide 
Measurement » 
HBMEC were first seeded in 4-well plates (ThermoFischer, Waltham, MA) and 
grown until confluent. Cells were washed with Hank’s Buffer (HBSS) and allowed to rest 
for 1 hr before addition of 200 U/ml of hyaluronidase (HYALase, H3506, Sigma-Aldrich) 
or 100 μg/ml of low molecular weight (LMW) HA (GLR001, R&D Systems) for 2 hours at 
37°C in a cell culture incubator. HYALase-treated cells were in a HBSS with 0.01% bovine 
serum albumin (BSA; A9647, Sigma-Aldrich) solution, while LMW HA-treated cells were 
in a HBSS solution. Hydrogen peroxide (H2O2) at 20 M was added to one of the wells as a 
positive control for the last 30 min of cell treatment in the reactive oxygen species (ROS) 
assay, while of 200 μM of diethylenetriamine NONOate (DETA) was used as a positive 
control in the nitric oxide (NO) assay. 
To measure the production of ROS content, HBMEC were loaded with 10 uM of 
dihydrorhodamine-123 (DHR; a pan-ROS specific fluorochrome) 1 hr into the 2 hr 
treatment and covered in the dark. After the treatment(s), cells were then washed with 
HBSS 3 times and lysed in a 1% sodium dodecyl sulfate (SDS) in PBS. Lysed cells were 
additionally sonicated for 30 seconds (Cole Parmer, Chicago, Illinois) and centrifuged at 
10,000 g at 4°C for 5 minutes. Clear supernatants were diluted with Milli-Q water and 
placed in a black-wall/clear-bottom 96-well plate (Corning Inc., Corning, NY). 
Fluorescence was read at an excitation and emission wavelength of 510 nm and 530 nm, 
respectively, on a microplate reader (VICTOR, Perkin Elmer).  
To measure endothelial nitric oxide (NO), cells were loaded with 4-amino-5-
methylamino-2',7'-difluorofluorescein diacetate (DAF-FM; NO-specific flurochrome) at a 
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concentration of 10 uM in the same loading conditions as DHR. Supernatants were then 
diluted with Milli-Q water in a 10 mm cuvette and read at an excitation of 490 nm and an 
emission of 515 nm on a spectroflurophotometer (Shimadzu RF-1501, Shimadzu Corp.).  
Protein levels of each sample used in the assays were determined via a 
bicinchoninic assay (BCA) kit (Sigma-Aldrich). Fluorescence values of the sample were 
then normalized to protein amount and control values. All samples were analyzed in 
triplicate readings. 
 
2.6 « Western Blotting of Extracellular Regulated 
Kinases (ERK) » 
HBMEC were seeded on a 4-well plate (ThermoFischer) and grown to confluency. 
Before treatment, cells were washed with HBSS and treated with or without 200 U/ml of 
HYALase (H3506, Sigma-Aldrich) in HBSS with 0.01% BSA for 30 min or 2 hours. Cells 
were then washed in cold PBS and lysed in a 1% SDS buffer with 1x PhosStop (Roche) and 
1x protease inhibitor cocktail (Sigma-Aldrich). Samples were boiled with a SDS sample 
buffer containing ß-mercaptoethanol for 5 min. Ten-percent acrylamide gels were used to 
separate the proteins and transferred onto a nitrocellulose membrane (162-0177, Bio-Rad, 
Hercules, California) overnight at 30 V and 4°C with the Mini Trans-Blot Cell (Bio-Rad). 
Membranes were blocked in 2% BSA (Sigma-Aldrich) in Tris-buffered saline (TBS) with 
0.05% Tween-20 (TBS-T) for 1hr at room temperature (RT).  Primary antibodies used were 
phospho-ERK1/2 (p-ERK1/2l 1:1000, ab50011, Abcam), total ERK1/2 (1:1000, ab17942, 
Abcam), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:5000, G8795, 
Sigma) at their respective dilutions. Primary antibodies were diluted in 5% BSA with TBS-
T and incubated overnight at 4°C. Peroxidase-coupled secondary antibodies used were 
rabbit anti-mouse (1:5000, ab97046, Abcam) and goat anti-rabbit IgG (1:5000, A27036, 
ThermoFischer). Secondary antibodies were diluted in TBS-T only and incubated for 1 hr 
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at RT. Membranes were washed in TBS-T before chemiluminescent substrate was added 
and read on a MicroChemi (FroggaBio, North York, Ontario) imager.  
Membranes were first probed with p-ERK1/2 before stripped at 60°C for 45 min in 
a harsh stripping buffer (2% SDS/0.78% β-mercaptoethanol). Membranes were re-blocked 
and then probed with total ERK1/2, imaged, and afterwards probed with the housekeeping 
gene, GAPDH. The ratio of phosphorylation in the densitometry values were compared 
between the two groups. The ratio between phosphorylation and the housekeeping gene 
(GAPDH) were also compared between the two groups.   
 
2.7 « Platelet Adhesion Assay » 
Enzymes degrading the glycocalyx may not cleave to the extent seen in 
inflammatory signals (i.e. TNF-α33) that cause shedding, possibly underestimating the role 
of the glycocalyx, which is why we chose to bolster GAGs in vitro instead of removing the 
glycocalyx for this functional assay.  
Blood from healthy volunteers that have not taken any anti-histamines or anti-
inflammatories for the past two weeks was drawn into citrate-containing tubes 
(Vacutainers®; BD Biosciences). Blood was centrifuged at 190 g for 15 min at RT with no 
break applied. The platelet-rich fraction of the plasma was removed to a new tube and 
EDTA was added to a final concentration of 7.7 mM. To collect the platelets, the sample 
was centrifuged at 600 g for 10 min at RT. The supernatant was discarded and the pellet 
was resuspended in Ca+2 /Mg+2-free HBSS as a wash. Platelets were centrifuged again at 
600 g for 10 min at RT and resuspended in Ca+2 /Mg+2-free HBSS. A cell count using a 
haemocytometer was done to determine a dilution of 1 x 108 platelets / ml and were 
incubated with 0.25 M of CellTracker™ Green CMFDA Dye (ThermoFischer) for 30 min 
at RT in the dark. After incubation, platelets were centrifuged at 600 g for 10 min at RT, 
resuspended in Ca+2 /Mg+2-free HBSS, and placed in the dark until ready for perfusion. 
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HBMEC were grown to confluence in μ-Slide VI0.4 channels (IBIDI, Martinsried, 
Germany) in regular EBM-2 supplemented media, while GAG-supplemented media 
included EBM-2 supplemented media with the addition of 20 g/ml of HS, 0.12 mg/ml of 
HA, and 0.12 mg/ml of CS. Half of the channels received GAG-supplemented media the 
night before perfusion, while the rest of the channels received regular EBM-2 
supplemented media. All perfusion parameters were performed at 37°C in a temperature-
controlled chamber, with a shear stress of 0.35 dyn/cm2 and a flow rate of 0.2 ml/min. The 
channels were perfused with pH-adjusted EBM-2 only for 1 min to replace the media. 
CMFDA-incubated platelets (1 × 107 platelets/ml in EBM-2) were perfused over the cell 
monolayer for 5 min and then rinsed with EBM-2 only for 1 minute. Cell monolayers were 
then fixed with 3% paraformaldehyde at 37°C for 20 min and washed in 1x PBS at RT. The 
number of fluorescent platelets remaining on the cell monolayer was analyzed by 
fluorescence microscopy (Zeiss Axiovert 200M; Carl Zeiss, Oberkochen, Germany), using 
a digital camera AxioCam MRc (Carl Zeiss) to obtain images. Fluorescent platelets were 
counted within each channel in 5 randomly chosen areas and expressed as a % of the 
control channel’s fluorescent platelets. 
 
2.8 « Statistical Analysis » 
All statistical analyses were done using Graphpad Prism software, with the 
threshold of significance being P < 0.05. Data are presented as mean + standard error 
(SEM). Data were assessed for normality using the D’Agostino-Pearson test before 
applying either a Student’s t-test for parametric data or a Mann-Whitney U-test for 
nonparametric data. Correlations were done using non-parametric Spearman correlation. 
One-sample T-test (parametric data) or Wilcoxon signed-rank test (non-parametric data) 
were done for samples that were normalized to control wells. Data with multiple groups 
were compared using the Kruskal-Wallis test and Dunn’s test for multiple comparisons.  
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3 « Results » 
3.1 « Study Patients » 
Plasma was obtained from T1DM pediatric patients, either with acute DKA or in an 
insulin-controlled state (CON). The two groups were age and sex matched (n = 20 
patients/group). Patients with DKA had significantly higher glycated hemoglobin (HbA1C) 
values (P < 0.0001), compared to the T1DM controls, reflecting sustained elevation of 
blood glucose over the previous few months (Table 1). DKA patients all had elevated blood 
glucose and were in severe metabolic acidosis (mean pH = 7.0, Table 1) compared to ideal 
pediatric ranges8. Over half of the DKA patients (n = 12) sampled had their first onset 
diagnosis of T1DM via the DKA episode.  
 
Table 1. Patient Clinical Data of Insulin-controlled Type-1 Diabetes Mellitus Patients 
(CON) or with Acute Diabetic Ketoacidosis (DKA) 
Clinical Data CON DKA P value 
Mean Age (years) 
Male : Female Ratio 
Body Mass Index Z Scores 
HbA1C (%) 
pH 
HCO3
- (mmol/L) 
pCO2 (mmHg) 
11.8 ± 0.7 
9:11 
0.76 ± 0.17            
8.3 ± 0.2 
N/A 
N/A 
N/A 
12.0 ± 0.7 
9:11 
0.27 ± 0.25 
11.9 ± 0.5 
7.0 ± 0.03 
5.8 ± 0.7 
20.3 ± 1.9 
0.808 
1.00 
0.109 
< 0.0001 
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Lactate (mmol/L) 
Blood glucose (mmol/L) 
N/A 
N/A 
2.7 ± 0.4 
29.3 ± 2.2 
 
 
Data is presented as mean ± SEM and n = 20 / group, except for HbA1C values for DKA 
patients where n = 19. Body mass index (BMI) Z-scores were missing for 4 DKA patients 
due to lack of height data and BMI was unable to be calculated. N/A represents data that 
was not obtained. A Mann-Whitney or an unpaired t-test was used to determine if there 
were any significant differences between CON and DKA, where P < 0.05 was considered 
significant. 
 
3.2 « ELISA measurements of plasma glycocalyx 
constituents » 
Glycocalyx components were measured in the plasma to determine if there was a 
specific shedding response in DKA patients compared to insulin-controlled T1DM controls 
(CON). There were significant elevations in both HA (8.7-fold increase) (Figure 3A) and 
HS (2.4-fold increase) (Figure 3B) in DKA patients (P < 0.001) compared to CON. No 
changes were seen between CON and DKA patients in SDC-1 (Figure 3C) and CS plasma 
levels (Figure 3D).  
Optical density (OD) values that exceeded the kit’s range were replaced with the 
maximal value in the kit’s range. Two DKA patients in the HA ELISA assay, and 2 
different DKA patients in the SDC-1 assay exceeded the max detectable range and were 
replaced. OD values that could not be read were replaced with zero. The SDC-1 levels of 1 
insulin-controlled T1DM patient and 1 DKA patient could not be detected and were 
replaced with zero.   
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Figure 3. Plasma Glycocalyx Constituents in Patients with Insulin-controlled Type-1 
Diabetes Mellitus (CON) or Acute Diabetic Ketoacidosis (DKA). 
A. HA plasma levels in DKA patients were significantly increased compared to CON 
patients. B. HS plasma levels in DKA patients were significantly increased compared to 
CON patients. C. SDC-1 plasma levels were not significantly different between CON and 
DKA patients. D. CS plasma levels were not significantly different between CON and 
DKA patients. Data presented for CS are reported in mean pg/ml + SEM. 
Optical density (OD) values that exceeded the kit’s range were replaced with the maximal 
value in the kit’s range. OD values that could not be read were replaced with zero. A Mann-
Whitney test was used to determine if there were any significant differences between CON 
A B 
D C 
23 
 
 
 
and DKA, where P < 0.05 was considered significant. Data presented are reported in mean 
ng/ml + SEM and n = 20 / group, unless otherwise specified. 
 
3.3 « Plasma glycocalyx correlations with DKA severity 
» 
Plasma glycocalyx constituents were then compared to several DKA parameters 
including blood pH, HbA1C, and bicarbonate (HCO3) levels to determine if there were any 
correlations. Only concentration of HA significantly correlated to pH severity, HbA1C 
levels, and bicarbonate levels. Lower pH (r = -0.6327, P = 0.0028, n = 20) and HCO3 levels 
(r = -0.4901, P = 0.0282, n = 20) correlated to higher levels of HA found in the plasma of 
DKA patients (Figure 4A and B), while higher HbA1C (r = 0.4809, P = 0.0371, n = 19) 
levels correlated to higher levels of HA found in the plasma of DKA patients (Figure 4C). 
A correlation to glycated hemoglobin, implicates HA shedding as related to the prolonged 
hyperglycemia period that patients experience before DKA occurs.  
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Figure 4. Correlations between plasma glycocalyx constituents and DKA parameters in 
DKA patients.  
A. Lower pH correlated with higher HA concentrations in DKA patients (P = 0.0028, n = 
20). B. Lower HCO3 concentration correlated with higher HA concentrations in DKA 
patients (P = 0.0282, n = 20). C. Higher glycated haemoglobin (HbA1c) correlated with 
higher HA concentrations in DKA patients (P = 0.0371, n = 19).  
A line of best fit was added to show the trend and is only for visual purposes. 
 
3.4 « Endothelial Reactive Oxygen Species (ROS) 
Assay » 
Bicarbonate derangement in DKA has been shown to be associated with CE 
incidence in DKA102 and since HA shedding also correlated to HCO3 levels, HA was either 
exogenously removed or added to determine if there were any proinflammatory effects on 
HBMEC cells. Although HYALase may not be the major cleaver of HA in DKA (Suppl. 
Figure 1), we used HYALase to stimulate the loss of HA on endothelial cells. Other 
sheddases (e.g. TNF-α) can activate proinflammatory signalling cascades and bring in 
confounding factors.  
ROS assays were used to determine if HA induce oxidative stress, as seen in CE of 
DKA60. Both LMW HA (P = 0.0078, n = 8) and HYALase (P = 0.002, n = 10) caused a 
significant increase in ROS production when compared to unstimulated HBMEC (Figure 
5). HYALase produced almost a 2 fold increase while LMW HA produced a 1.3 fold 
increase in ROS production, suggesting both the cleaving of HA and the HA fragments can 
be implicated in generation of oxidative stress. Interestingly, treating HBMEC with 
heparinase (1 U/ml) showed no significant changes in ROS production (data not shown). 
The concentration of LMW HA used in this study was chosen based on a range of in vitro 
studies seen in literature95,176. HYALase concentrations were chosen based on physiological 
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levels in T1DM patients132 and treatment time was based on reduction of the glycocalyx 
layer as seen in another study209.  
The amount of HA found within the media was also measured via ELISA to 
determine that HA existed on the cell monolayers to be shed into the media and that 
HYALase was capable of cleaving HA. The amount of HA in the HYALase treatment was 
undetectable because the ELISA kit could only detect HA fragments larger than 45 kDa, 
indicating that HYALase in our treatment condition was capable of cleaving HA (Suppl. 
Figure 2). The ELISA kit has also been used to determine the efficacy of HYALase activity 
in another study by measuring the decrease in HA detection147.  
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Figure 5. Effect of exogenous LMW HA and HYALase on ROS production in naïve 
(unstimulated) HBMEC. 
HBMEC were treated with LMW HA, HYALase, or H2O2 (as a positive control) for 2 hrs 
and assessed for ROS production with respect to intracellular oxidation of DHR123. Data 
** P < 0.01 
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presented are rhodamine fluorescence values expressed as mean + SEM and were 
normalized by protein content via BSA assay and unstimulated control HBMEC values. 
LMW HA (P = 0.0078, n = 8), HYALase (P = 0.002, n = 10), and H2O2 (P = 0.0078, n = 8) 
had significantly higher ROS production as compared to control (dotted line). A non-
parametric, Wilcoxon signed-rank test was done to determine any significant differences 
compared to control.  
 
3.5 « Endothelial Nitric Oxide Production Assay » 
Endothelial NO production was measured to determine if HA could induce 
nitrosative stress on naïve HBMEC, similar to the nitrosative stress as seen in CE in 
DKA165. Obtained data indicate that HYALase (P = 0.002) treatment caused a significant 
decrease in levels of NO compared to unstimulated control or positive control (i.e. DETA) 
(Figure 6). HYALase treated HBMEC resulted in almost a 70% decrease of fluorescence, 
while there were no significant changes after LMW HA treatment. These findings indicate 
that HYALase-dependent removal/cleavage of HA but not the HA fragments per se on an 
intact glycocalyx, is responsible for reducing endothelial NO levels.   
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Figure 6. Effect of exogenous LMW HA and HYALase on NO production in naive 
(unstimulated) HBMEC. 
HBMEC were treated with LMW HA, HYALase, or DETA (as a positive control) for 2 hrs 
and assessed for NO production with respect to intracellular fluorescence of DAF-FM. Data 
presented are DAF-fluorescence values expressed as mean + SEM and were normalized to 
protein content via BSA assay and unstimulated control HBMEC values. HYALase-treated 
cells had significantly lower levels of NO compared to control (dotted line) (P < 0.0001, n 
= 10). A parametric one sample t-test was used to determine any significant differences.  
 
3.6 « Western Blotting of Phospho-ERK1/2 and Total 
ERK1/2 » 
The mitogen-activated protein kinases (MAPK)-associated signaling (e.g. ERK, 
JNK and p38) was explored as a potential signal transducing pathway relevant to the 
increased oxidative stress. MAPK/ERK is known as a mediator of inflammatory genes in 
**** P < 0.0001 
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response to stimulation with LMW HA in other cell types (e.g. mesothelial, vascular 
endothelial)74,200,81. HBMEC cells were treated with HYALase for either 30 min or 2 hrs 
before levels of p-ERK1/2 and total ERK1/2 were quantified via western blot. As cell 
signalling changes may occur earlier than the changes seen in the chemical ROS/NO 
assays, an earlier time point was also assessed. The obtained results indicate that HYALase 
significantly increased levels of p-ERK2 (P < 0.05, Figure 7B) but not p-ERK1 (Figure 7A, 
Suppl. Figure 3) at both experimental time points. GAPDH was also probed as a control for 
loading and the levels of p-ERK1/2 relative to GAPDH were not significantly different.  
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Figure 7. ERK1/2 phosphorylation in HBMEC stimulated with HYALase. 
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HBMEC were stimulated with HYALase for 30 min or 2 hrs and assessed for ERK1/2 
activation via phosphorylation. A. Representative image of p-ERK1/2, total ERK1/2, and 
GAPDH western blots. B. The ratio between the phosphorylation of ERK2 and total ERK2 
were calculated and expressed as a percentage. A Kruskal-Wallis test was done to show a 
significant increase in density compared to control conditions at 30 min and 2 hrs. Data is 
shown as mean % + SEM phosphorylation of ERK2. To correct for multiple comparisons, 
Dunn’s test was used to determine significance (*P < 0.05). Comparisons were only made 
according to each respective timed control (30 min, n = 5; 2 hrs, n = 7). 
 
3.7 « Platelet Adhesion Assay » 
The glycocalyx can inhibit platelet adhesion via steric hindrance49 and masking of 
glycoproteins154. Understanding that DKA is of a prothrombotic and proinflammatory 
nature, we determined if an intact, augmented glycocalyx would prevent adhesion. HBMEC 
were supplemented with GAGs overnight before naïve, unstimulated platelets were 
perfused over. All three major GAG components were supplemented as there were 
significant increases in HS and HA shedding in DKA plasma and multiple studies have 
used CS in complement with the other GAGs to therapeutically restore the glycocalyx77,170. 
When HBMEC were grown in supplemented GAG media, there was a significant decrease 
(P < 0.05, n = 6) in platelet adhesion when compared to control indicating that platelet 
adhesion (Figure 8) is inhibited by an optimal glycocalyx layer. 
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Figure 8. Platelet adhesion on HBMEC monolayers grown in normal EBM-2+ (CON) or 
EBM-2+ with GAGs supplementation (+HA/HS/CS).  
Data is presented as a ratio to the number of platelets found compared to control + SEM. 
HBMEC monolayers that had media supplemented with GAGs showed a decrease in 
platelet adhesion (P < 0.05, n = 6). A non-parametric, Wilcoxon signed-rank test was used 
to determine if there was any difference compared to control.  
 
3.8 « Negative Experimental Data » 
There are 4 additional supplemental figures that returned negative data, as we 
experimentally looked at several functional assays under the treatment of exogenously 
addition/removal of GAGs: integrity (Suppl. Figure 4) and permeability of HBMEC assays 
(Suppl. Figure 5) and leukocyte adhesion assays (Suppl. Figure 6-7).  
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4 « Discussion » 
Experiments were conducted to quantify glycocalyx constituents in DKA plasma 
and to correlate glycocalyx levels to DKA severity. Data suggests that DKA patients are 
undergoing increased glycocalyx shedding compared to their insulin-controlled T1DM 
counterparts and cleavage of the glycocalyx can lead to an activated and prothrombotic 
state on the endothelial cells characterized by ROS production and depressed basal NO. 
Our findings of decreased platelet adhesion on an optimal glycocalyx agree with current 
literature that a loss of glycocalyx can lead to an increase risk of microvascular dysfunction 
and thrombosis as seen in DKA.  
 
4.1 « Glycocalyx Status in DKA » 
We looked to determine the role of GAGs in vascular dysfunction in DKA as the 
glycocalyx have been shown to be a modulator in various inflammatory diseases and 
involved in many roles of the endothelium. We found an 8.7-fold increase in HA and a 2.4-
fold increase in HS (Figure 3) under DKA conditions compared to T1DM. Inflammatory 
diseases that similarly have increased HA and/or HS shedding include trauma151, diabetic 
angiopathy118, ischemic stroke2 and sepsis131; all indicating that the loss of HA and HS are 
involved with the pathogenesis of vascular deterioration. T1DM patients have higher levels 
of HA and HYALase compared to healthy non-diabetic controls: implicating that DKA 
patients are undergoing a greater level of HA shedding134. Increased HA shedding can be 
attributed to the inflammatory and hyperglycemic state of DKA, where healthy controls 
when given a hyperglycemia insult, plasma HA levels were increased along with a reduced 
glycocalyx volume135.  
The increase of HS in DKA compared to T1DM may not have as great of a fold 
change as HA because T1DM patients may already have altered sulfation of HS as seen in 
human biopsies92 samples and low HS levels due to increased excretion106 compared to 
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non-diabetic patients. Although levels of SDC-1 were not significantly elevated in DKA 
patients, SDC-1 is a protein adhered into the cell through a transmembrane domain191 and 
has been known to be increased in plasma under conditions of diabetic nephropathy115,172,92, 
where the basement membranes of the renal tubules are also undergoing HS changes. 
Noting that SDC-1 is a marker of trauma88 and severe vascular damage (e.g. 
hemorrhage181) SDC-1 shedding may be more of an indicator of severe endothelial 
membrane damage or protease activity, and is not seen in DKA patients unless secondary 
complications like clinical CE occurs.  
 
4.1.1 « Increased HA in DKA Plasma 
One of the primary roles of free HA is to be a mediator of inflammation more so 
than procoagulation. Addition of medium molecular weight (MMW) HA (250-1000 kDa) 
onto unstimulated endothelium or PMNs3 provides little to no effect, but the results 
dramatically differ when low (10-250 kDa) or short (< 10 kDa) HA are added, especially to 
activated cells. This is not surprising, as HA turnover produces medium-sized HA 
fragments and is fairly constitutive with 1/3 of HA being replaced daily and around 10-100 
mg of HA entering the blood per day37,175. Short HA can act as a DAMP as it is usually 
only produced in acidic endosomes162,72. HA acting as a DAMP can be found to activate 
many inflammatory pathways such as induction of chemokine and MMP genes in mouse 
macrophages168, MMP-9 and IL-8 mRNA upregulation in tumor cells112, and rapid tyrosine 
phosphorylation and proliferation in endothelial cells198.  
High molecular weight ( > 1000 kDa, HMW) HA has been recognized as essential 
for anti-inflammatory142, antiangiogenic and immunosuppressive properties, but can also 
vary depending on the cell type it acts on197. Pretreatment with HMW HA can be 
protective137 to inflammation and apoptosis as the molecular fractions of HA usually shifts 
to decreased amounts of HMW HA to increased MMW or LMW HA as seen in 
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inflammatory models of asphyxia139, lung inflammation in fibrosis176, skin wounds46, and 
knee osteoarthritis10.  
The effect of free HA also depends on context and size-specific conditions. As the 
ELISA kit limits the detectable length of HA to be no shorter than 35 kDa, it is unclear 
whether the effect of free HA is of a proinflammatory or anti-inflammatory nature. 
However, the increased amounts of HA found in DKA plasma is most likely part of the 
inflammatory response. HA shedding caused by inflammatory disorders such as acute lung 
injury have been known to be proinflammatory and of a LMW nature84. Other 
inflammatory responses such as cigarette smoke exposure18,103, atherosclerosis lesions17, 
and aortic catheter injuries26, have all shown an increase in LMW HA after stimulation.  
LMW HA can bind via TLR-2 in endothelial cells to stimulate a lower 
proinflammatory response (e.g. upregulating E-selectin and IL-8) in comparison to 
canonical inflammatory cytokines such as TNF-a150, indicating that LMW HA acts as a 
primer on ECs for further activation. LMW HA can induce IL-8 transcription and 
production via TLR-4 after 8 hours on dermal endothelial cells175. Another aspect affected 
by the plasma are the immune cells, including macrophages, and PMNs. Human 
macrophages stimulated with LMW HA have been shown to have increased MMP-9 
activity, while HMW HA downregulated MMP-9 activity17. The activity of MMP-9 from 
PMNs and endothelial cells can also be induced by LMW HA150. Potentiating the effect of 
MMPs would further the endothelial dysfunction, as HMW HA binds tightly to CD44201, 
which if broken, could increase MMP-9 docking to endothelial CD44. However, LMW HA 
may also be necessary for proper inflammatory responses, as it can induce neutrophil 
apoptosis in protection from an inflammatory lung injury response107, once again showing 
the context specificity manner of HA. 
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4.1.2 « Increased HS in DKA Plasma  
HS has a duality nature in propagating inflammation. Intact HS on the glycocalyx is 
used to slow neutrophil and monocyte rolling velocity via L-selectin64,165, while free HS act 
as a chemotactic gradient towards the damaged area164, implicating HS as a crucial player in 
the endothelial inflammatory processes that can facilitate CE. Free HS could bind up 
cytokines such as IL-2182, IFN-y76, IL-10160, or enhance its activity such as preventing its 
degradation in IL-6128 or have a synergistic effect on cell proliferation with IL-5109. 
Heparinase-cleaved fragments of HS in human mononuclear cells can induce cytokine 
release (IL-1B, IL-6, IL-8, IL-10, and TNFα) via TLR-4 pathway67. Increases in free HS 
detected in the plasma can then contribute to the inflammatory profile of DKA patients 
where there is a significant increase in IL-6, CXCL-1, and IL-8 levels138. In fact, free HS 
can bind to IL-8 to increase neutrophil cystolic free Ca+2 and chemotaxis by 4-fold196. 
Increases in cytokine activity, or leukocyte activation on the endothelium would 
inevitably activate platelet adhesion through release of vWF as P-selectin is revealed on the 
surface of ECs149. The duality exists too for platelet adhesion, as IL-8 upregulates PAF, 
while TNF-α promotes an anti-thrombotic state in the vasculature via increased NO24. HS is 
known to bind antithrombin to inhibit the coagulation cascade, however the knock-out of a 
sulfation enzyme needed for HS in mice did not reflect a prothrombotic state, indicating 
that another GAG (such as CS) may be responsible in compensating for the antithrombin 
binding197 when HS is not available.  
 
4.1.3 « Source of Glycocalyx Shedding » 
Glycocalyx shedding has primarily two consequences, the removal of glycocalyx 
from the source and the free glycocalyx constituents within the blood. The increase in 
shedding found in DKA could be due to changes of degradation or synthesis of HA. HA 
synthesis enzymes (HAS) are usually found to produce HMW to MMW HA, while only 
HAS-3 secretes HA of a lower weight (100 kDa – 1000 kDa)175. Some cytokines like TNF-
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α can enhance HA surface levels without changes in mRNA for HAS or HYALase123, 
while other cytokines (e.g. IL-1B, TGFB) can alter transcription of HAS163. However the 
more proinflammatory lengths of HA are not seen to be naturally synthesized, but created 
through degradation124. The two degradation pathways of HA involve HYALase-1 or 
HYALase-2 but both are CD44 dependent124. HYALase-1 is the HYALase primarily found 
in the plasma42, but its activity is only optimal at a pH range of 4.0 and found intracellularly 
in lysosomes to cleave HA down to tetrasaccharides72,194. HYALase-1 is unique in that its 
activity hydrolyzes CS faster than HA, showing duality as a lysosomal enzyme206. The 
ability of HYALase-1 to cleave HA to tetrasaccharides at low pH intracellularly indicates 
why LMW HA acts as a DAMP.  HYALase-2 is linked to the cell membrane and degrades 
HA to 20 kDA fragments194, which can stimulate inflammatory cytokine production72. It 
has an optimal pH at 6-7 and HYALase-2’s degrading activity is potentiated when detected 
with co-expression of CD4472. Knowing that the plasma pH of DKA is fairly acidic (Table 
1), the activity of HYALase-2 is optimized in severe DKA. Although HYALase was not 
found to be significantly increased in DKA plasma (Suppl. Figure 1), a trend exists and 
HYALase may not be free floating in the plasma, but bound on to the cell surface acting on 
the glycocalyx instead, like the mechanism of HYALase-2. 
The loss of the glycocalyx can lead to increased platelet adhesion12 and platelets are 
a rich source of HYALase-2 and heparinase. Platelet-origin HYALase-2 could cleave HA 
off endothelial cells and those fragments subsequently act as an inflammatory signal to 
monocytes45. However, there are serum HYALase inhibitors (ascorbic acid80, inter-alpha-
inhibitor (IαI) derived122, HS compounds63) that need to be accounted for and how they 
interact with the plasma HYALase-1 and cell-surface bound HYALase-2 remains unclear. 
HYALase are not the only pathways of producing LMW HA, as ROS activity can 
fractionate HA to LMW HA54 and increase HYALase-2 activity in epithelial cells via P38 
MAPK125. Other proteinases commonly found at inflammatory sites such as cathepsin B, 
elastase, and proteinase-3 all increase HA shedding, but whether that is due to degradation 
of HA or the HA-bound receptor CD44 remains unclear12. ROS production via neutrophil 
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degranulation of elastase and MMP8/9 is implied in DKA202, and thus, the increases in HA 
shedding can be accounted for and as well participate in facilitating inflammation through 
free HA fragments.   
4.1.4 « Consequences of Glycocalyx Shedding » 
Although the actions of LMW HA may be proinflammatory, the removal of HA on 
endothelial cells may actually be protective. Studies have shown that removal of HA on 
activated endothelium have resulted in decreased CD44/HA-mediated rolling of 
lymphocytes88 and adhesion in neutrophils129. There are other methods for leukocytes to 
bind to the endothelium through integrins and HA is not required for the adhesion in 
neutrophils129. There may be an additional insult required in order for the removal of HA on 
the endothelium to be no longer protective, as HYALase-treated rats under a model of 
asphyxia led to worse outcomes210, or that an accumulation of LMW HA (such as in the 
microvasculature) is more likely to potentiate proinflammatory effects as cleaved HA is 
cleared away after HYALase-treatment. A majority of the studies done with LMW HA 
have also used long incubation periods150 indicating that cells may require persistent or 
elevated levels of LMW HA to be stimulatory.  
The role of HA shedding is likely to be a consequence of prolonged hyperglycemia 
and an inflamed circulation. In DKA, the majority of the HA appears to be shed from the 
endothelium, as the levels of HA are a representative marker of endothelial damage since it 
correlates to pH severity, extent of hyperglycemia, and bicarbonate imbalance in DKA 
patients (Figure 4). Although there may be an increased production of HA123, there is much 
more evidence that under inflammatory conditions, an increase in GAGs in the media or 
circulation reflects a decrease in glycocalyx thickness in the vasculature 
endothelium12,20,21,126,174. The effects of increased plasma HA could mean a degradation of 
protective HMW HA, an increase of LMW HA acting as mostly proinflammatory signals, 
or increased shedding of the endothelium as a protective response.  
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4.2 « Microvasculature Dysfunction » 
Next, we looked to see if the endothelial microvascualture would have any 
dysfunction after HA shedding by examining the chemical aspect of endothelial activation 
and prothrombotic conditions. 
 
4.2.1 « Increased ROS after HA Cleavage » 
Both LMW HA and HYALase resulted in an increase in intracellular ROS, 
indicating that it is most likely the increase in free LMW HA that is causing the HBMEC to 
increase in ROS production in comparison to control rather than the cleavage of HA from 
HBMEC (Figure 5). LMW HA has been shown to stimulate ROS production via NADPH 
oxidases in vascular smooth muscle189 and macrophages via CD4471 in vitro. Shedding of 
HA could then exacerbate the increased ROS production via NADPH oxidases as cells 
undergoing hyperglycemia, similarly have overactivation of NADPH oxidases83 dependent 
on the protein kinase C pathway199. Exogenous ROS on platelet activity appears to be dose-
dependent and relies on superoxides reacting with NO, limiting the NO bioavailability to 
increase platelet aggregation97.  
 
4.2.2 « Decreased NO after HA Cleavage » 
Next, we looked at one of the major inhibitors of platelet activation – NO. The 
reduction of NO seen in only HYALase treated HBMEC indicates that the first step of 
removing HA from endothelial cells is necessary to cause a decrease in NO, rather than 
only the cleaved products of HA (Figure 6). Under healthy endothelial cells, circulating HA 
would not dysregulate NO production. Due to the short treatment time, the changes in NO 
are most likely due to an endothelial NO synthase (eNOS) as it regulates short bursts of NO 
in a calcium-dependent manner121,199.  In endothelial cells, when HA is removed, the 
association of CD44, inositol triphosphate receptors (calcium channels), ankyrin 
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(cytoskeleton protein), and caveolin-1167 (CAV-1) falls apart. CAV-1 and heat shock 
protein-90 usually remain bound to eNOS59 as an inhibitor in unstimulated cells207. Without 
HA stabilizing the congregation of calcium channels and CAV-1 via CD44, eNOS would 
be further inhibited and basal NO production would be decreased. In vivo naturally 
expressed HA in renal endothelial cells show clustering of CD44, and if inhibited, shows 
reduced clustering207 impacting the possibility of CD44 being grouped into caveolae. 
Increased ROS as seen above, can reduce bioavailability of NO by creating peoxynitrite, 
which is another molecule that can disrupt endothelial caveolae grouping with eNOS28.  
In the vasculature of diabetic patients, the endothelium has been known to have 
dysfunctional NO productivity resulting in an increase of superoxide availability and 
NADPH protein expression41,83. Increased C-reactive protein (CRP) circulating in diabetic 
patients can also suppress basal NO release via decreased mRNA availability190. CRP is 
commonly found to be increased in T1DM patients43 and associated to systemic 
inflammatory response syndrome in DKA98. NO is essential in dynamic endothelial 
responses as it acts as an anti-inflammatory regulator by mitigating VCAM-1 expression 
after cytokine stimulation on endothelial cells44, reduce superoxide production40, and 
adhesion on leukocytes61, and basal inhibition of platelet activation161. Peroxynitrite is 
catalyzed faster than hydrogen peroxide from superoxides28 and in low concentrations can 
inactivate the antithrombotic prostacyclin synthase213. Depressed NO has also been found 
in other inflammatory diseases such as atherosclerosis137, myocardial ischemia and 
perfusion114, and hypercholesterolemia104, giving a strong indication that when the 
endothelium is under an inflammatory response, NO production is dysregulated.  
NO is important in cerebral blood flow regulation. Cleaving of HS57 or HA141 
blocked shear induced NO production, essential in adjusting vascular tone to changes in 
cerebral blood pressure179. HA can act as a mechanotransducer by binding to and clustering 
the CD44 receptor in caveolae to phosphorylate eNOS, leading to NO production in 
response to shear stress173. The loss of HA and HS can then contribute to the impaired 
autoregulation found in DKA patients113. NO has also been shown to ameliorate the 
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impaired CO2 vasoreactivity in patients with endothelial dysfunction (DM or 
hypertension)102, implicating the importance of NO production in the dynamic acidic 
environment during DKA onset. The lack of HA to produce a counter NO vasodilation to 
the vasoconstrictive hypocapnia119,156 in DKA could lead to increased fluid influx and risk 
of thrombosis. Shedding of the glycocalyx would then be a contributor to the NO 
dysfunction found in the endothelium of DKA patients. 
Under hyperglycemic conditions, oxidative stress increases while NO 
bioavailability is decreased in endothelial cells41,87. DKA patients with fatal CE have been 
found to have increased oxidative and nitrosative stress markers within the brain78,79. 
Increased cleavage of HA from the endothelium or circulating LMW HA in the plasma of 
DKA can facilitate and participate in the increased oxidative state of the brain endothelium, 
while shedding of the HA from the endothelium would result in lowered NO production, 
possibly affecting cerebral autoregulation and playing a major role in the prothrombotic 
state of DKA. 
 
4.2.3 « Increased ERK2 phosphorylation under HYALase-treated 
HBMEC » 
To narrow down the effect of elevated shedding of HA seen in the increase in ROS 
or decrease in NO, we looked into ERK cascades to see if it was involved in facilitating the 
responses. There was a strong increase in ERK2 phosphorylation compared to control 
(Figure 7B) when HBMEC was stimulated with HYALase for 30 min or 2 hr. Similarly, 
ERK phosphorylation increased due to the addition of HA or LMW HA in human lung 
endothelial cells111. However, another study using bovine endothelial cells showed only 
increased ERK1 phosphorylation168 but the fragments used were of fairly small 
oligosaccharides and HA has been known to be cell-type specific142. Oligosaccharides of 
HA have also been shown to increase ERK1/2 phosphorylation dependent on CD44 
transiently within 5 minutes in placental endothelial cells195.  
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Within our model, it is hard to distinguish between which size of HA is acting on 
the cells as HA is a repeating disaccharide, but it appears that LMW HA is the likely 
instigator of ERK phosphorylation as seen in other studies. HA fragments binding onto 
TLR-4 can facilitate cytokine production as seen in previous studies175,176. The breakdown 
of HMW-HA could also be a facilitator of inflammation, as HMW-HA is needed to inhibit 
stimulated TLR-4 signaling via decreasing ERK1/2 phosphorylation205. As both HYALase 
(Figure 7) and exogenous HA74,111,168 in other cells can activate ERK phosphorylation in 
endothelial cells, this pathway seems to be involved with ROS production rather than NO 
inhibition. In endothelial cells, ROS have been known to increase permeability in the brain 
microvasculature by downregulating tight junctions via ERK phosphorylation56. The ROS 
produced by HYALase could be increasing ERK phosphorylation instead of direct 
interaction between HA and ERK phosphorylation. Shedding of HA can then facilitate 
increased ROS to promote ERK phosphorylation, increased permeability at the BBB in 
DKA, and lead to CED. 
 
4.3 « Inhibition of Platelet Adhesion via Enhanced 
Glycocalyx »   
Lastly, we wanted to establish the relationship between platelet adhesion and 
integrity of the glycocalyx on endothelial cells. DKA is known to be a prothrombitic state27, 
indicating that increased platelet aggregation can release enzymes to further degrade the 
glycocalyx and facilitate cerebrovascular complications. Increased platelet aggregation in 
DKA patients can be detrimental especially in young pediatric patients where there is a 
50% increased rate of clinical deep venous thrombosis when inserting a central venous 
catheter58. Acute hyperglycemia studies have also shown that a loss of endothelial 
glycocalyx correlates to increased platelet adhesion133, while some studies point to the lack 
of NO bioavailability as a contributor to platelet aggregation65,159. Although clinically, there 
have been reports of increased procoagulation factors in DKA patients58, a recent report has 
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suggested it is not the platelets that are activated, but instead the authors suggest an 
endothelial nature to the prothrombotic state of DKA183.  
The glycocalyx is known to regulate coagulation cascades, as HS can inactivate 
thrombin via anti-thrombin III178 or bind to tissue factor pathway inhibitor154 to prevent 
coagulation. The negative charge of the glycocalyx can also repel platelets from 
approaching the endothelial cells6 and as a mechanotransducer affecting NO bioavailability, 
we looked to see if supplementing an in vitro model of the microvasculature with GAGs 
would bolster the glycocalyx to reduce platelet adhesion. Our results show that when 
supplementing the media with GAGs, platelet adhesion is reduced (Figure 8) when 
compared to cell monolayers grown under normal media. Although our ELISA results 
show that our model possess HA (Suppl. Figure 2), the glycocalyx layer may not be as 
developed as in vivo models. Cleaving of the glycocalyx on the cell monolayer may result 
in little to no change in adhesion or rolling as seen in experiments with PMN 
rolling/adhesion and HYALase on naïve HBMEC (Suppl. Figure 6-7), similar to heparinase 
which showed no changes in white blood cell adhesion after infusion127. Destabilization of 
the glycocalyx may result in removal of selectins required for rolling and adhesion, 
implicating that shedding may be a natural response to inflammation127. In support of that, 
removal of HA on rat fibrosarcoma cells have also shown to diminish platelet adhesion94. 
However, further degradation may overwhelm the protective effect as knockouts of CD44 
(that binds to HA) had the opposing effect110. 
Our results show a decrease in platelet adhesion after GAG supplementation in 
HBMEC. This is consistent with the literature, where pretreatment with Sevoflurane, a 
vapour anesthetic and protector of glycocalyx degradation, lead to reduced platelet 
adhesion in ischemic-reperfusion in guinea pig hearts32. When glycocalyx is removed via 
oxidative stress in vivo, platelet adhesion increased and diminished as the oxidative stress 
was inhibited192. Overall, an intact glycocalyx is associated with decreased platelet 
adhesion. The glycocalyx is important in maintaining NO bioavailability as described 
above, and in particular of endothelial cells, NO tonically inhibits platelet activation in 
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healthy human volunteers161. Consequentially, the glycocalyx and NO availability have 
been essential to creating biomaterial for medical devices to reduce platelet adhesion when 
implanted in the vasculature166. The depression of endothelial NO by HYALase-treated 
HBMEC (Figure 6) also implicate the glycocalyx’s contribution to the prothrombotic state 
of DKA.  
 
4.4 « Clinical Significance and Limitations » 
4.4.1 « Clinical Significance » 
We have elucidated the glycocalyx status in DKA patients, with findings of 
increased shedding of HA and HS compared to their insulin-controlled counterparts. Our 
experiments have also shown that shedding of HA can contribute to endothelial dysfunction 
via increase in ROS, and a prothrombotic endothelial state via depressed NO production. 
We have demonstrated that perturbed glycocalyx can contribute to increased platelet 
adhesion, leading to increased susceptibility for prothrombotic events in DKA patients, and 
opening up the glycocalyx as a possible therapeutic avenue (Figure 9). 
 
4.4.2 « Limitations » 
Several limitations are to be noted. There is a trend of higher enzyme activity of 
HYALase in the plasma of DKA compared to insulin-controlled T1DM patients (Suppl. 
Figure 1), but despite the lack of significance, according to the literature, we would expect 
a higher in vivo activity as HYALase enzymes have an optimal pH of 7 or lower73. 
Therefore in DKA patients, HYALase activity should be much higher during acidosis and 
at sites of PMN degranulation90. Not all the HYALase enzymes may be free floating in the 
plasma, as they may be docked to the endothelial wall and cleaving HA before being 
endocytosed into the cell as most HYALase enzymes are72. The Morgon-Elson reaction 
assay39 used to determine HYALase requires that both plasma samples be in a buffer of pH 
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4.0, eliminating the natural pH difference between the two conditions, and the HYALase 
enzymes may be inhibited through HS, or a circulating inhibitor122 that is part of the IαI 
family in the plasma. The HYALase used in our in vitro model was of a mammalian origin, 
but not human. Bovine HYALase could have also cleaved HA in different MW fragment 
ratios compared to human HYALase, which could represent different contexts of the HA 
environment presented to the cells, and lead to different intracellular responses143. 
Our BBB model is also of a static nature, therefore the effect of altered NO 
production may be minimized when shear flow is not accounted for and the status of the 
glycocalyx is unknown. Although a recent paper has shown that a cellular in vitro model is 
capable of developing a full glycocalyx50, while others have shown an insufficient layer of 
glycocalyx via different techniques33. Our model lacks other factors when accounting for 
DKA, such as the hyperglycemia and ketoacidosis.  
 
4.4.3 « Future Directions » 
One of the future directions is to look for the main mechanism of shedding, whether 
it is mainly attributed to the prolonged hyperglycemia, an enzyme, or the increased 
activation of PMNs, should be explored as a therapeutic direction. Future studies are 
required to look at the specific size and context the HA is being shed and consequently, the 
downstream effect to better predict its role in inflammation and susceptibility to secondary 
complications, like CE. The damaged glycocalyx in DKA can be safely repaired through IV 
supplementation of GAGs and should be targeted as a potential therapeutic intervention, 
similarly in septic shock170. Platelet studies should be taken to an in vivo DKA model and 
the glycocalyx should be reconstituted with GAG supplementation to measure the effect on 
thrombotic events and platelet adhesion. There have been studies on antithrombin 
preventing glycocalyx degradation30 as a therapeutic treatment, however, one study points 
to antithrombin’s inhibitory effects were on proteases as the mechanism of action instead of 
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platelets themselves34. Ameliorating the glycocalyx may be the other main mechanism to 
reduce platelet adhesion and the prothrombotic tendency of DKA patients.  
 
4.5 « In Conclusion » 
Overall, shedding of the glycocalyx in DKA has been shown to be specific in HA 
and HS, however it is only HA that correlated to severity of DKA. HS and HA can 
potentiate the major circulating cytokines (IL-8/IL-6) in DKA patients to exacerbate the 
damage in the endothelium. HA appears to be representative of the endothelium health, as it 
acts as a modulator to the inflammatory response via immune and endothelial molecules. 
Specifically in HBMEC cells, removal of HA or exogenous addition of LMW HA can 
stimulate ROS production leading to endothelial dysfunction. Only the removal of HA from 
HBMEC would suppress NO production and combined with the ROS production status, it 
points to a prothrombotic response from the endothelium (Figure 9). Platelet adhesion is 
also decreased when cells are grown with a GAG supplementation, implicating the role the 
protective role of a glycocalyx to prevent thrombotic events. Overall, the shedding of the 
glycocalyx in DKA patients is an indicator of endothelial health and patients with increased 
shedding should be observed closely for susceptibilities to dysfunctional endothelial 
complications, such as thrombosis and CE.  
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Figure 9. Proposed mechanism of microvascular dysfunction leading to CE and thrombosis 
in DKA patients as adapted from Woo (2015)204.  
Prolonged hyperglycemia and ketoacidosis increases circulating proinflammatory 
cytokines and induce glycocalyx shedding. The proinflammatory state in DKA can recruit 
PMNs to the inflamed endothelial cell surface, which may have also lost its glycocalyx, 
leading to easier access to the endothelial cells attenuating microvascular leak through 
degranulation of proteases. Both degranulated proteases and glycocalyx fragments can then 
potentiate circulating cytokines in a positive feedback loop to recruit more immune cells to 
the microvasculature. Meanwhile, loss of the glycocalyx increases ROS production and 
decreases endothelial NO production, a potent inhibitor of coagulation. Decreased NO 
bioavailability can prime the endothelial cells into a prothrombotic state, leading to 
increased risk of thrombosis in DKA patients. We propose that microvascular dysfunction 
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complications, such as CE or thrombosis found in DKA, can be attributed to the breakdown 
of the BBB via protease activity, increased ROS production, decreased basal coagulation 
inhibition via depressed NO, and shedding of the glycocalyx to expose the ECs to immune 
cells. 
Compared to the dysfunction found in DKA, healthy endothelium have an intact 
glycocalyx that covers over adhesion molecules and glycoproteins needed for rolling and 
adhesion of platelets and PMNs, provides sufficient NO bioavailability, and acts as a 
negative steric barrier, separating entities away from the endothelial cell.  
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Appendices 
As there was increased HA shedding found in the plasma of DKA patients, 
HYALase activity was also measured to quantify if any differences in HYALase activity 
can be detected between the plasma of insulin-controlled T1DM (CON) and DKA patients. 
The obtained data indicates that there were no significant differences in the HYALase 
activity of CON and DKA patients. Important to note, we observed a slight trend of 
increased HYALase activity in the plasmas of DKA patients (Suppl. Figure 1, P = 0.087, n 
= 25).  A larger sample analysis may be necessary to determine statistical significance.  
 
 
Supplementary Figure 1. Plasma HYALase activity in insulin-controlled T1DM (CON) 
and DKA patients. 
Data is presented as mean g/ml + SEM. Assays were done in triplicate (n = 25/group) and 
an unpaired t-test was used to determine significance (P < 0.05). No significant differences 
were found (P = 0.087), however there is a trend of increased HYALase activity in DKA 
plasma compared to CON.  
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Supernatents of the in vitro model HBMEC model were tested after changing the 
cells in HBSS to determine if there were any free floating HA shed into the medium (Suppl. 
Figure 2). As HYALase was left in the medium, any free floating HA would have been 
cleaved to fragments below the detectable limit of the HA ELISA kit, indicating that in 
both conditions, HA was present on the cells and HYALase was capable of cleaving HA 
fragments to molecular weights below 45 kDA.  
 
 
Supplementary Figure 2. HA detected by ELISA in Supernatents of HBMEC monolayers 
with or without HYALase treatment.  
The detectable range of HA on the ELISA kit was >45 kDa and all of the HYALase 
supernatents had no detectable HA via ELISA, as the size most likely fell below the 
detection limit. Data is shown as mean + SEM. A non-parametric Mann-Whitney test was 
used to determine any significant differences (P<0.001, n = 8).   
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Supplementary Figure 3. Densitometric quantification of ERK1 phosphorylation in 
HBMEC stimulated with HYALase 
The ratio between phosphorylation of ERK1 and total ERK1 levels were calculated and 
expressed as a percentage. A Kruskal-Wallis test was done to determine no significant 
differences in density of HYALase treated wells compared to control conditions at 30 min 
and 2 hrs. Data is shown as mean % + SEM phosphorylation of ERK1. To correct for 
multiple comparisons, Dunn’s test was used to determine significance (*P < 0.05). 
Comparisons were only made according to each respective timed control (30 min, n = 7; 2 
hrs, n = 9) 
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Permeability of the in vitro HBMEC model was tested through 2 separate ways, 
using an electric cell-substrate impedance sensing system (ECIS) (Suppl. Figure 4) and a 
trans-well system (Suppl. Figure 5) under HYALase and LMW HA treated conditions. We 
wanted to determine if shedding of the HA or proinflammatory LMW HA would increase 
permeability, leading to a role in CE. No changes in permeability were found. This is found 
to be consistent in the literature, where the trans-endothelial barrier is maintained, but the 
surface layer may be thinner51.  
 
Supplementary Figure 4. Resistance Measurements of LMW HA or HYALase on naïve 
HBMEC cells via Electric Cell-substrate Impedance Sensing (ECIS) 
Each condition had its own control well. Data is shown as % of baseline resistance from 
before treatment compared to after 2 hr treatment of LMW HA (100 g/ml), HYALase 
(200 U/ml), or control media. A non-parametric, Mann-Whitney test was used to determine 
any significant differences. There were no significant differences in resistance changes 
between each treatment to its respective control (LMW HA: n = 4, HYALase: n = 3). 
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Supplementary Figure 5. HBMEC Permeability after Heparinase and/or HYALase 
treatment determined via Fluorescein isothiocyanate-Dextran 
Data is presented as mean fluorescence + SEM. HBMEC monolayer permeability was 
determined by the amount of fluorescent 3k-Dextran in the lower chamber of the transwell 
after 2 hr treatments. A non-parametric, Kruskal-Wallis test was used to determine any 
significant differences (n = 4). No significant differences were found between control and 
any of the enzyme treatments.    
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Adhesion and rolling of PMNs were tested after HYALase and/or heparinase 
treatment on naïve HBMEC cells to determine if glycocalyx removal would be able to 
induce endothelial activation. First, we applied the treatment only to naïve HBMEC cells to 
work with stimulating one compartment at a time (Suppl. Figure 6). Next we stimulated 
both compartments that would be exposed to glycocalyx shedding (Suppl. Figure 7). In 
both experiments, treatments did not induce a functional endothelial activation state.  
 
 
 
A 
Adhesion of PMNs 
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Supplementary Figure 6. PMN adhesion and rolling after treatment of HYALase and/or 
Heparinase on naïve HBMEC monolayers.  
Data is presented as mean PMNs/area + SEM. A non-parametric, Kruskal-Wallis test was 
used to determine any significant differences. A. Amount of PMN adhesion on HBMEC 
monolayers, averaged over 5 randomly selected areas. There were no significant 
differences between the enzyme treatments and control (HYALase: n = 10, 
Heparinase/Heparinase with HYALase: n = 5). B. Amount of PMN rolling on HBMEC 
monolayers over 5 minutes after treatments. Outliers greater than 2 standard deviations 
were discarded. There were no significant differences between the enzyme treatments and 
control (n = 4)   
 
 
B 
Rolling of PMNs 
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Supplementary Figure 7. PMN adhesion and rolling after treatment of HYALase on naïve 
HBMEC monolayers and PMNs. 
Data is presented as mean PMNs/area + SEM. Naïve HBMEC monolayers were stimulated 
for 2 hrs with HYALase, while PMNs were stimulated with HYALase 5 min before 
perfusion. To determine statistical significance, a Mann-Whitney test applied. A. Amount 
of PMN adhesion on HBMEC monolayers, averaged over 5 randomly selected areas. There 
B 
Rolling of PMNs 
A 
Adhesion of PMNs 
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were no significant differences in PMN adhesion between HYALase and control (CON: n = 
7, HYAL n = 6). B. Amount of PMN rolling on HBMEC monolayers over 5 minutes after 
treatments. There were no significant differences between HYALase and control (n = 7).  
 
70 
 
 
 
Supplementary Attachment 1: Ethics approval 
 
107 
 
 
 
  
71 
 
 
 
Curriculum Vitae 
 
Name:   Rufina Ning 
 
 
 
Post-secondary  University of Western Ontario 
Education and  London, ON 
Degrees:   Bachelor of Science 
   Honours Specialization in Physiology and Pharmacology 
   2012-2016 
 
 
 
 
Honours and  Pediatrics Graduate Grant 
Awards:   University of Western Ontario 
2016-2017 
 
 
  
 
 
Meetings   Physiology and Pharmacology Research Day 2017 
Attended:    Western University 
Poster Presenter 
   
   London Health Research Day 2017 and 2018 
   London, ON, Canada 
   Poster Presenter 
 
 
